Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. - Wikidata - awgldk - TriplyDB

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

http://www.wikidata.org/entity/Q33370812

about

Waldenstrom's macroglobulinemia: Recent advances in biology and therapy The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Targeted therapy in lymphoma.Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Proteasome inhibitors in mantle cell lymphoma Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Bortezomib for multiple myeloma.Use of bortezomib in B-cell non-Hodgkin's lymphoma.The role of bortezomib in the treatment of lymphoma.Treatment of adult T-cell leukemia/lymphoma: past, present, and future.HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.Bortezomib in mantle cell lymphoma.Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.Mantle cell lymphoma: state-of-the-art management and future perspective.New targets of therapy in T-cell lymphomas.Novel disease targets and management approaches for diffuse large B-cell lymphoma.Optimal treatment for relapsing patients with Hodgkin lymphoma.

P2860

Q28269017-1C8D15D6-658F-450F-92AA-25858A3789FB Q30248842-A01D496D-FB05-4297-9CC8-629320113AD0 Q33385670-9BE8F8C9-279F-4882-AC01-1496A08B2140 Q33394873-9D4A9755-A3A1-42E6-A0AE-1704F239F656 Q33396522-C8FC528B-567C-482C-B787-17577432334F Q33404090-9DCE4FFF-D023-4EAB-BF23-2C5CC34DDEDC Q33414307-C00F73D0-F4AE-46C9-9FB0-1D461CF11A5D Q33414603-F05C7F27-7F57-4C18-A921-09A7D5FF3390 Q33418257-2F70B666-EABF-4A70-9964-3C37949D6E44 Q33669018-B0F75805-21F0-4887-9725-4BCE7CB57F64 Q33798887-A2FBF62B-2B74-4A59-99AD-DC7FAD623534 Q34106817-CF6E6AAA-F523-43E6-BF5D-B0A72B9CAF85 Q34413686-7B685EAA-9C48-447C-A280-FFC2BB86749C Q34541718-9F8E36B0-C5E8-44C7-8B05-AC462A8B1525 Q34608608-4F96FE3A-E02D-4764-AB3F-C87A3D17B1D9 Q34707136-5F709CA9-4610-4EC5-BCF3-0469C928037F Q35009005-54E5C3AA-CEAD-4DD4-B8E7-4507BF131521 Q35022833-365F7AF3-B99D-4099-AEC4-C9FAEE3CE4B4 Q35050501-7E89BEEA-A610-47EB-8B97-72C57F8129E6 Q35779961-B3A6F2FA-51DC-4C0E-B53B-78B0427C9F0E Q35905929-036D1DFB-6263-433C-AD9A-9224952B7DF4 Q35933211-B888E48C-1986-4351-921F-E18E88B41429 Q35989980-09B640B4-8A25-477C-A7B6-4F3ACCDBACC5 Q36028745-4F701620-62F8-439E-B1B3-F2DF8D4C5466 Q36117384-414D2819-ABDD-46B9-8FD6-64645EE96C40 Q36456078-39F2BC41-698F-43AF-8C80-1AC00935E035 Q36521862-B8EB38D5-8EA1-40B4-835B-7CE07B3CEFE6 Q36532076-18B85206-5191-44A8-B1DF-39DF82CB9E9E Q37024073-0013C718-8700-4B24-A6EB-E4EDC392C628 Q37032793-063819EC-BD06-414D-93A6-21065F79B4F9 Q37079191-7AE52920-E262-4E9E-9E11-4740659DB7EA Q37136989-761212AD-3F7E-4D52-A4DF-1DA7E1F3A0BF Q37136999-60E69817-56C4-4098-8A62-ED95D615AA2B Q37140809-F53EE46B-206C-411A-AEC2-DA7604E750D2 Q37187543-9336BE84-DAEC-408A-8F7B-C2060DFD0C2C Q37326210-10ECEC4F-AFAB-41B4-98B8-A485F6ADB3E7 Q37622873-7EEF6023-9F30-4DBC-9CF7-36A9E851190A Q37701472-60D1A288-1183-4DD4-B298-7919853C159D Q37775632-23B783A6-FA1C-4447-8DE9-1DFCA84F1734 Q37810094-82DBECFF-E27A-4BE4-998F-2BBBECF726AB

P2860

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

http://www.wikidata.org/entity/Q33370812

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Bortezomib therapy in patients ...... sponse with clinical activity.

@ast

Bortezomib therapy in patients ...... sponse with clinical activity.

@en

type

label

Bortezomib therapy in patients ...... sponse with clinical activity.

@ast

Bortezomib therapy in patients ...... sponse with clinical activity.

@en

prefLabel

Bortezomib therapy in patients ...... sponse with clinical activity.

@ast

Bortezomib therapy in patients ...... sponse with clinical activity.

@en

P1433

Q33370812-D2C4F1DC-2B1B-4DB8-A1FC-B022EFC9FF41

P1476

Q33370812-3277972F-AF25-4535-AE22-4CE5209CECF9

P2093

Q33370812-02DA1CFE-120C-4778-AC56-EC3D28E6DD11

Q33370812-070BBFF2-6F99-4C66-A2F2-FF42773501B6

Q33370812-277B60AB-4F14-4532-A806-B3E4C7093D8C

Q33370812-31599B2B-B36D-4CA8-AE89-0946CCF01859

Q33370812-4C87F39E-638A-449E-9CDB-31ABBFAC1426

Q33370812-A7D515D1-1D9E-409E-83BA-48541D94D4C2

Q33370812-BF4A587B-E079-4CE3-BE92-8AD6EF63C8D1

Q33370812-C32D93B0-E7F2-4329-A0B7-BC1B7D71082E

Q33370812-E2EDB5CF-2E09-40D5-99BE-4271791B5261

Q33370812-E3AE7FBA-1589-490E-B4A3-44638452A691

P304

Q33370812-EA9CDCC0-9A94-41B6-AAF3-120F74AD7697

P31

Q33370812-1BD4D3BD-CAD5-4539-AC96-61ACB2154D3F

P356

Q33370812-A27654BE-51FA-4A98-9E57-89916EEF1D52

P407

Q33370812-40DFE1E7-3A99-4396-A00F-B6F8A59450EB

P433

Q33370812-ADB05333-36F2-4B58-987F-1588EBC9C767

P478

Q33370812-85A74A4B-303C-4160-BD12-4A7246F02FCD

P50

Q33370812-17D22DE7-D562-4736-9CF4-19F1E36ED9AC

Q33370812-71F0A0D1-498C-4700-9E12-BF76303D33B8

Q33370812-C6815D49-2BEA-4CB0-8AE8-4375F6E2D0DC

P577

Q33370812-84FB7CB6-5580-4C02-9DBE-E81A6DF6882C

P698

Q33370812-EB4558A1-67A8-4DC3-90FA-36C2EBD1F85D

P356

JCO.2005.04.6789

P1433

Journal of Clinical Oncology

P1476

Bortezomib therapy in patients ...... sponse with clinical activity.

@en

P2093

Ama Rohatiner

http://www.w3.org/2001/XMLSchema#string

Anthony Boral

http://www.w3.org/2001/XMLSchema#string

David Schenkein

http://www.w3.org/2001/XMLSchema#string

Elizabeth Trehu

http://www.w3.org/2001/XMLSchema#string

Lenushka Maharaj

http://www.w3.org/2001/XMLSchema#string

Lynda Millard

http://www.w3.org/2001/XMLSchema#string

Sandra J Strauss

http://www.w3.org/2001/XMLSchema#string

Sarah Vinnecombe

http://www.w3.org/2001/XMLSchema#string

Simon P Joel

http://www.w3.org/2001/XMLSchema#string

Susan Hoare

http://www.w3.org/2001/XMLSchema#string

P304

2105-2112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.04.6789

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Frances R Balkwill

Peter W Johnson

P577

2006-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16606971

http://www.w3.org/2001/XMLSchema#string